|
1
|
Farazi PA and DePinho RA: Hepatocellular
carcinoma pathogenesis: From genes to environment. Nat Rev Cancer.
6:674–687. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Simonetti RG, Liberati A, Angiolini C and
Pagliaro L: Treatment of hepatocellular carcinoma: A systematic
review of randomized controlled trials. Ann Oncol. 8:117–136. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mas VR, Fisher RA, Archer KJ, Yanek KC,
Williams B, Dumur CI and Maluf DG: Genes associated with
progression and recurrence of hepatocellular carcinoma in hepatitis
C patients waiting and undergoing liver transplantation:
Preliminary results. Transplantation. 83:973–981. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moradpour D and Blum HE: Pathogenesis of
hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 17:477–483.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nam SW, Park JY, Ramasamy A, Shevade S,
Islam A, Long PM, Park CK, Park SE, Kim SY, Lee SH, et al:
Molecular changes from dysplastic nodule to hepatocellular
carcinoma through gene expression profiling. Hepatology.
42:809–818. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Poon TC, Wong N, Lai PB, Rattray M,
Johnson PJ and Sung JJ: A tumor progression model for
hepatocellular carcinoma: Bioinformatic analysis of genomic data.
Gastroenterology. 131:1262–1270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teufel A, Staib F, Kanzler S, Weinmann A,
Schulze-Bergkamen H and Galle PR: Genetics of hepatocellular
carcinoma. World J Gastroenterol. 13:2271–2282. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schafer DF and Sorrell MF: Hepatocellular
carcinoma. Lancet. 353:1253–1257. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mas VR, Maluf DG, Archer KJ, Yanek K, Kong
X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P, et al:
Genes involved in viral carcinogenesis and tumor initiation in
hepatitis C virus-induced hepatocellular carcinoma. Mol Med.
15:85–94. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodda DJ, Chew JL, Lim LH, Loh YH, Wang B,
Ng HH and Robson P: Transcriptional regulation of nanog by OCT4 and
SOX2. J Biol Chem. 280:24731–24737. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bass AJ, Watanabe H, Mermel CH, Yu S,
Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, et
al: SOX2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Y, Shi L, Zhang L, Li R, Liang J, Yu
W, Sun L, Yang X, Wang Y, Zhang Y, et al: The molecular mechanism
governing the oncogenic potential of SOX2 in breast cancer. J Biol
Chem. 283:17969–17978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hussenet T, Dali S, Exinger J, Monga B,
Jost B, Dembelé D, Martinet N, Thibault C, Huelsken J, Brambilla E,
et al: SOX2 is an oncogene activated by recurrent 3q26.3
amplifications in human lung squamous cell carcinomas. PLoS One.
5:e89602010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hussenet T and du Manoir S: SOX2 in
squamous cell carcinoma: Amplifying a pleiotropic oncogene along
carcinogenesis. Cell Cycle. 9:1480–1486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Justilien V, Walsh MP, Ali SA, Thompson
EA, Murray NR and Fields AP: The PRKCI and SOX2 oncogenes are
coamplified and cooperate to activate Hedgehog signaling in lung
squamous cell carcinoma. Cancer Cell. 25:139–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schoenhals M, Kassambara A, De Vos J, Hose
D, Moreaux J and Klein B: Embryonic stem cell markers expression in
cancers. Biochem Biophys Res Commun. 383:157–162. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang P, Qiu J, Li B, Hong J, Lu C, Wang
L, Wang J, Hu Y, Jia W and Yuan Y: Role of Sox2 and Oct4 in
predicting survival of hepatocellular carcinoma patients after
hepatectomy. Clin Biochem. 44:582–589. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun C, Sun L, Li Y, Kang X, Zhang S and
Liu Y: Sox2 expression predicts poor survival of hepatocellular
carcinoma patients and it promotes liver cancer cell invasion by
activating Slug. Med Oncol. 30:5032013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao C, Li Y, Zhang M, Yang Y and Chang L:
miR-126 inhibits cell proliferation and induces cell apoptosis of
hepatocellular carcinoma cells partially by targeting Sox2. Hum
Cell. 28:91–99. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blank C, Kuball J, Voelkl S, Wiendl H,
Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R,
et al: Blockade of PD-L1 (B7-H1) augments human tumor-specific T
cell responses in vitro. Int J Cancer. 119:317–327. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y,
Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, et al: Upregulation of
circulating PD-L1/PD-1 is associated with poor post-cryoablation
prognosis in patients with HBV-related hepatocellular carcinoma.
PLoS One. 6:e236212011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nomi T, Sho M, Akahori T, Hamada K, Kubo
A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al:
Clinical significance and therapeutic potential of the programmed
death-1 ligand/programmed death-1 pathway in human pancreatic
cancer. Clin Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Butte MJ, Keir ME, Phamduy TB, Sharpe AH
and Freeman GJ: Programmed death-1 ligand 1 interacts specifically
with the B7-1 costimulatory molecule to inhibit T cell responses.
Immunity. 27:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park JJ, Omiya R, Matsumura Y, Sakoda Y,
Kuramasu A, Augustine MM, Yao S, Tsushima F, Narazaki H, Anand S,
et al: B7-H1/CD80 interaction is required for the induction and
maintenance of peripheral T-cell tolerance. Blood. 116:1291–1298.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Paterson AM, Brown KE, Keir ME, Vanguri
VK, Riella LV, Chandraker A, Sayegh MH, Blazar BR, Freeman GJ and
Sharpe AH: The programmed death-1 ligand 1:B7-1 pathway restrains
diabetogenic effector T cells in vivo. J Immunol. 187:1097–1105.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Motzer RJ, Rini BI, McDermott DF, Redman
BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S,
Logan TF, et al: Nivolumab for metastatic renal cell carcinoma:
results of a randomized phase II trial. J Clin Oncol. 33:1430–1437.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Robert C, Ribas A, Wolchok JD, Hodi FS,
Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et
al: Anti-programmed-death-receptor-1 treatment with pembrolizumab
in ipilimumab-refractory advanced melanoma: A randomised
dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M,
Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression
of PD-L1 significantly associates with tumor aggressiveness and
postoperative recurrence in human hepatocellular carcinoma. Clin
Cancer Res. 15:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Y, Wang H, Wang X, Jin W, Tan Y, Fang
H, Chen S, Chen Z and Wang K: Genome-wide studies identify a novel
interplay between AML1 and AML1/ETO in t(8;21) acute myeloid
leukemia. Blood. 127:233–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matys V, Kel-Margoulis OV, Fricke E,
Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M,
Hornischer K, et al: TRANSFAC and its module TRANSCompel:
Transcriptional gene regulation in eukaryotes. Nucleic Acids Res.
34:D108–D110. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin R, Maeda S, Liu C, Karin M and
Edgington TS: A large noncoding RNA is a marker for murine
hepatocellular carcinomas and a spectrum of human carcinomas.
Oncogene. 26:851–858. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sakamoto M: Early HCC: Diagnosis and
molecular markers. J Gastroenterol. 44:(Suppl 19). 108–111. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu X, Liu RF, Zhang X, Huang LY, Chen F,
Fei QL and Han ZG: DLK1 as a potential target against cancer
stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther.
11:629–638. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang
JY, Yang YP, Tien P and Wang FS: PD-1 and PD-L1 upregulation
promotes CD8(+) T-cell apoptosis and postoperative recurrence in
hepatocellular carcinoma patients. Int J Cancer. 128:887–896. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan X, Cang X, Dan S, Li J, Cheng J, Kang
B, Duan X, Shen B and Wang YJ: Site-specific disruption of the
Oct4/Sox2 protein interaction reveals coordinated mesendodermal
differentiation and the epithelial-mesenchymal transition. J Biol
Chem. 291:18353–18369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scaffidi P and Bianchi ME: Spatially
precise DNA bending is an essential activity of the sox2
transcription factor. J Biol Chem. 276:47296–47302. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and
Xu N: Immunohistochemical localization of programmed death-1
ligand-1 (PD-L1) in gastric carcinoma and its clinical
significance. Acta Histochem. 108:19–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
